Table 2.

Preceding Reports on Serial Measurement of Serum Ferritin and Anti-MDA5 Antibody.

Report category	Intervals between points of measurement	Key findings of serum biomarker level and associated factors		Reference
		Ferritin	Anti-MDA5 antibody
Observational study	2 or 3 months	Decreased and patients survived	Decreased and patients survived	9
Observational study	2-13 months	Decreased after remission of ILD	Decreased after remission of ILD	21
Observational study	2-40 weeks	Not assessed	Decreased to below cut-off level after improvement of ILD	19
Observational study	5-15 years	Not assessed	Decreased to below cut-off level after remission of ILD	20
Case report	4-74 days	Decreased and patient survived	Decreased and patient survived	5
Case report	10-20 days	Increased during patients needed oxygen supplementation	Not assessed	10
Case report	2-27 days	Increased during decreasing of PaO2/FiO2 ratio	Not assessed	11
Case report	2-11 days	Increased and the patient died	Decreased, but the patient died	-

ILD: interstitial lung disease, MDA5: melanoma differentiation-associated gene 5, PaO₂/FiO₂: arterial partial pressure of oxygen/fraction of inspired oxygen